| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9328382 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
Our data demonstrate that AKAP-3 is expressed at high frequency in patients with EOC. Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Sameer Sharma, Feng Qian, Bernadette Keitz, Deborah Driscoll, Mathew J. Scanlan, Jonathan Skipper, Kerry Rodabaugh, Shashikant Lele, Lloyd J. Old, Kunle Odunsi,